SEC EDGAR · Federal Reserve · FDA · BLS · Updated every 60s
Nakamoto Inc. paid down $45 million in debt by selling ~600 Bitcoin, entered new loan terms extending $105 million to June 2027, and authorized a $25 ...
Spark I Acquisition Corporation signed a merger agreement with ZincFive Inc, effective June 11, 2026, combining the SPAC with the target company. The ...
Theriva Biologics published Phase 1 clinical trial results demonstrating that VCN-01 oncolytic adenovirus combined with durvalumab produced prolonged ...
Enliven Therapeutics announced updated positive Phase 1 data for ELVN-001 in chronic myeloid leukemia with 61% overall response rates and FDA alignmen...
J.W. Mays reported nine-month revenues of $15.8M versus $16.8M year-ago, with net losses widening to $1.1M versus $44K losses in the prior period. The...
InspireMD announced positive 30-day results from CGUARDIANS II trial showing 100% acute device success with zero major adverse events for its CGuard P...
Caribou Biosciences reported long-term data for vispa-cel CAR-T therapy showing 82% overall response rate and 67% complete response rate in second-lin...
Vera Bradley achieved its first quarter of overall revenue growth since Q4 FY22, with net revenues growing 7.8% year-over-year and non-GAAP gross marg...
Prairie Operating Co. executed a second amendment to its credit agreement effective April 1, 2026, redetermining and reaffirming its borrowing base at...
Atossa Therapeutics has issued common stock purchase warrants exercisable beginning December 12, 2026, with terms defined in a June 10, 2026 Securitie...
Rafael Holdings completed enrollment in its pivotal Phase 3 TransportNPC trial for Niemann-Pick disease Type C and expects to submit an NDA in the sec...
Silence Therapeutics presented Phase 1 follow-up data showing divesiran reduced phlebotomy requirements from 80 procedures to 5 during treatment, with...
Driven Brands reported first-quarter revenue of $484.4 million with 2% same-store sales growth and improved net leverage to 3.2x Adjusted EBITDA. The ...
Xeris Biopharma agreed to retire approximately $23 million of 8.00% Convertible Senior Notes due 2028 through private exchanges, reducing annual inter...
McGraw Hill reported fiscal year 2026 revenue of $2.1B with recurring revenue up 5.8% and returned to profitability with $35.3M net income. The compan...
Nurix Therapeutics announced updated Phase 1a/b clinical trial results showing a 92.9% objective response rate in second-line CLL patients treated wit...
C4 Therapeutics released a corporate presentation showcasing its TORPEDO platform and protein degradation technology for disease treatment. The filing...
Orthofix Medical amended its Second Amended and Restated Stock Purchase Plan to increase the total reserved shares to 6,100,000. The expansion provide...
Cabaletta Bio modified its capital structure to authorize 593.6M voting common shares, 6.4M non-voting common shares, and 10M preferred shares. The am...
Lovesac delivered flat year-over-year net sales with modest market share gains while preparing for record product launches including a high-end sectio...